Hánah N Rier1,2, Agnes Jager3, Marieke C Meinardi4, Joost van Rosmalen5, Marc C J M Kock6, Peter E Westerweel7, Marija Trajkovic7, Stefan Sleijfer3, Mark-David Levin7. 1. Department of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3318, Dordrecht, AT, the Netherlands. rier@asz.nl. 2. Department of Medical Oncology, Erasmus Medical Center Cancer Institute, 's-Gravendijkwal 230, 3015, Rotterdam, CE, the Netherlands. rier@asz.nl. 3. Department of Medical Oncology, Erasmus Medical Center Cancer Institute, 's-Gravendijkwal 230, 3015, Rotterdam, CE, the Netherlands. 4. Department of Geriatric Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3318, Dordrecht, AT, the Netherlands. 5. Department of Biostatistics, Erasmus MC, Wytemaweg 80, 3015, Rotterdam, CN, the Netherlands. 6. Department of Radiology, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3318, Dordrecht, AT, the Netherlands. 7. Department of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3318, Dordrecht, AT, the Netherlands.
Abstract
PURPOSE: Assessing physical reserve in older cancer patients before treatment decision-making remains challenging. The maintenance of physical independence during therapy is sometimes just as important for these patients as oncological outcomes. Recently, sarcopenia has been recognized as a possible important prognostic factor for outcome in cancer patients. We investigated the association between different levels of sarcopenia and the decline of physical independence during chemotherapy in older cancer patients (≥ 65 years). METHODS: Sarcopenia was divided into presarcopenia, sarcopenia, and severe sarcopenia according to an international consensus and was related to physical independence determined by measuring instrumental activities of daily living (IADL), using binary logistic regression models. CT-based muscle mass is necessary to diagnose sarcopenia and was related to five functional tests, in order to investigate whether these easy-to-perform tests could replace the more invasive CT-based muscle measurement. RESULTS: A total of 131 patients were included (median age 72 years). The prevalence of presarcopenia, sarcopenia, and severe sarcopenia was 47.7, 18.5, and 7.7%, respectively. Compared to no sarcopenia, only severe sarcopenia seemed associated with a decline of physical independence after chemotherapy (OR 5.95, 95% CI 0.76-46.48). Muscle mass was only significantly associated with muscle strength, but not with tests measuring physical function. CONCLUSION: The level of sarcopenia might be a useful tool in addition to routine oncological assessment to identify older cancer patients with increased risk of physical decline after chemotherapy.
PURPOSE: Assessing physical reserve in older cancerpatients before treatment decision-making remains challenging. The maintenance of physical independence during therapy is sometimes just as important for these patients as oncological outcomes. Recently, sarcopenia has been recognized as a possible important prognostic factor for outcome in cancerpatients. We investigated the association between different levels of sarcopenia and the decline of physical independence during chemotherapy in older cancerpatients (≥ 65 years). METHODS:Sarcopenia was divided into presarcopenia, sarcopenia, and severe sarcopenia according to an international consensus and was related to physical independence determined by measuring instrumental activities of daily living (IADL), using binary logistic regression models. CT-based muscle mass is necessary to diagnose sarcopenia and was related to five functional tests, in order to investigate whether these easy-to-perform tests could replace the more invasive CT-based muscle measurement. RESULTS: A total of 131 patients were included (median age 72 years). The prevalence of presarcopenia, sarcopenia, and severe sarcopenia was 47.7, 18.5, and 7.7%, respectively. Compared to no sarcopenia, only severe sarcopenia seemed associated with a decline of physical independence after chemotherapy (OR 5.95, 95% CI 0.76-46.48). Muscle mass was only significantly associated with muscle strength, but not with tests measuring physical function. CONCLUSION: The level of sarcopenia might be a useful tool in addition to routine oncological assessment to identify older cancerpatients with increased risk of physical decline after chemotherapy.
Authors: V A Hughes; W R Frontera; M Wood; W J Evans; G E Dallal; R Roubenoff; M A Fiatarone Singh Journal: J Gerontol A Biol Sci Med Sci Date: 2001-05 Impact factor: 6.053
Authors: Anne B Newman; Varant Kupelian; Marjolein Visser; Eleanor M Simonsick; Bret H Goodpaster; Stephen B Kritchevsky; Frances A Tylavsky; Susan M Rubin; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2006-01 Impact factor: 6.053
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: V E Arango-Lopera; P Arroyo; L M Gutiérrez-Robledo; M U Pérez-Zepeda; M Cesari Journal: J Nutr Health Aging Date: 2013-03 Impact factor: 4.075
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: Ingrid C De Backer; Goof Schep; Adwin Hoogeveen; Gerard Vreugdenhil; Arnold D Kester; Eric van Breda Journal: Arch Phys Med Rehabil Date: 2007-05 Impact factor: 3.966
Authors: Kah Poh Loh; Vivian Lam; Katey Webber; Simran Padam; Mina S Sedrak; Vivek Musinipally; Madison Grogan; Carolyn J Presley; Janice Grandi; Chandrika Sanapala; Daniel A Castillo; Grace DiGiovanni; Supriya G Mohile; Louise C Walter; Melisa L Wong Journal: J Natl Compr Canc Netw Date: 2021-04-15 Impact factor: 12.693